Skip to main content
SpringerLink
Log in

ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Frohlich A, Niebel D, Fietz S, Egger E, Buchner A, Sirokay J, et al. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients. Cancer Immunol Immunother. 2020;69(5):759–69.

    Article  Google Scholar 

  2. Stahlie EHA, Franke V, Zuur CL, Klop WMC, van der Hiel B, Van de Wiel BA, et al. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model. Cancer Immunol Immunother. 2021;70(8):2291–300.

    Article  CAS  Google Scholar 

  3. Stahlie EHA, Carr MJ, Zager JS, van Akkooi ACJ. External validation of a Dutch predictive nomogram for complete response to T-VEC in an independent American patient cohort. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-11111-w.

  4. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658–67.

    Article  CAS  Google Scholar 

  5. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-1119.e10.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, The Netherlands

    Emma H. A. Stahlie MD & Alexander C. J. van Akkooi MD, PhD

Authors
  1. Emma H. A. Stahlie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander C. J. van Akkooi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma H. A. Stahlie MD.

Ethics declarations

Disclosures

Alexander C.J. van Akkooi reports advisory board and consultancy honoraria (all paid to the institute and unrelated to the current work) from Amgen, Bristol-Myers Squibb, Novartis, 4SC, Merck-Pfizer, MSD-Merck, Sanofi, and Sirius Medical. Emma H.A. Stahlie has made no disclosures.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stahlie, E.H.A., van Akkooi, A.C.J. ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC. Ann Surg Oncol 29, 1645–1646 (2022). https://doi.org/10.1245/s10434-021-11113-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-11113-8

Search

Navigation